Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Acrivon Therapeutics, Inc. ( (ACRV) ) is now available.
On March 19, 2026, Acrivon Therapeutics reported fourth quarter and full-year 2025 results, highlighting progress in its registrational-intent Phase 2b trial of ACR-368 in endometrial cancer, including a 52% confirmed overall response rate in serous endometrial cancer versus 22% in non-serous disease. The company has completed exploratory Arm 2 using ACR-368 plus ultra low-dose gemcitabine in biomarker-negative patients, initiated Arm 3 in all-comer serous endometrial cancer, and plans to launch Arm 4 testing ACR-368 monotherapy in biomarker-unselected serous endometrial cancer in 2026, while early Phase 1 data for ACR-2316 show encouraging activity in lung cancer, and cash of $118.6 million as of December 31, 2025 is expected to fund operations into the second quarter of 2027.
Acrivon also advanced its broader precision medicine infrastructure by launching a CLIA-certified laboratory for patient testing and companion diagnostic development, and nominating ACR-6840 as an internally discovered oral CDK11 inhibitor for future clinical development. Financially, the company narrowed its net loss to $19.0 million for the fourth quarter and $77.9 million for 2025, with lower research and development and general and administrative expenses year over year, underscoring disciplined spending as it seeks to strengthen its position in high-unmet-need oncology indications such as serous endometrial cancer and AP3-prioritized solid tumors.
The most recent analyst rating on (ACRV) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Acrivon Therapeutics, Inc. stock, see the ACRV Stock Forecast page.
Spark’s Take on ACRV Stock
According to Spark, TipRanks’ AI Analyst, ACRV is a Neutral.
The score is held down primarily by weak financial performance—no revenue, large and persistent losses, and substantial cash burn—despite low leverage. Technicals remain soft with the stock below key short- and mid-term moving averages, while valuation support is limited due to losses and no dividend. Offsetting these risks, recent positive clinical data and pipeline progress modestly improve the outlook.
To see Spark’s full report on ACRV stock, click here.
More about Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology, using its proprietary Generative Phosphoproteomics AP3 platform to design and develop targeted cancer therapies. Its lead program, ACR-368, is a CHK1/CHK2 inhibitor in a potentially registrational Phase 2 trial for endometrial cancer, with additional pipeline candidates ACR-2316 and ACR-6840 aimed at AP3-identified tumor types.
Average Trading Volume: 1,751,295
Technical Sentiment Signal: Sell
Current Market Cap: $51.75M
Find detailed analytics on ACRV stock on TipRanks’ Stock Analysis page.